







an Open Access Journal by MDPI

Advances in Tumor Epigenetics Research

Guest Editor:

Dr. Andrea Piunti

Department of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL 60611, USA

Deadline for manuscript submissions:

closed (26 April 2021)

Message from the Guest Editor

Dear Colleagues,

The notion that genetic alterations are not the only underlying cause of cancer formation and progression has been increasingly supported in the recently published literature. Among epigenetics alterations, chromatin deregulation is arguably one of the main contributing factors that promote cancer. It is therefore not surprising that an increasing number of cancers present with recurrent chromatin aberrations that are sometimes even demonstrated by recurrent genetic mutations at multiple chromatin machinery genes. Efforts aimed to develop potential therapies to target or take advantage of chromatin alterations are currently under development. This Special Issue will highlight the molecular basis of cancers with highly deregulated chromatin dynamics as well as the efforts to develop chromatin-related therapeutics.

Dr. Andrea Piunti *Guest Editor*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan

Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Message from the Editor-in-Chief

Genes are central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fastmoving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised.

Why not consider *Genes* for your next genetics paper?

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank: JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))

Contact Us